Highlights Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
7.765 ^USD	+2.04%		+20.57%	+70.66%

Mar. 19	North American Morning Briefing : Stock Futures -2-	DJ
Mar. 14	Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Larimar Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich?S Ataxia	Mar. 11	CI
Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia	Feb. 12	CI
Larimar Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Larimar Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Larimar Therapeutics Gets FDA Clearance to Proceed With Trials; Shares Rise	23-07-25	MT
Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial	23-07-25	CI
Larimar Therapeutics Poised to Join Russell 3000 Index	23-06-22	MT
Larimar Therapeutics Phase 2 Dose Exploration Study Shows CTI-1601 'Generally Well Tolerated' in Friedreich's Ataxia Trial	23-05-15	MT
Larimar Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Larimar Therapeutics Reports Preliminary Top-Line Data from Phase 2 Trial’S 25 Mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’S Ataxia	23-05-15	CI
Larimar Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-14	CI
Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Larimar Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-14	CI
Larimar Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Larimar Therapeutics Gets US Patent Providing Extended Protection for CTI-1601 Through at Least 2040	22-10-20	MT
Larimar Gets FDA Clearance to Start 25 Mg Cohort of Mid-Stage Study of CTI-1601 in Friedreich's Ataxia Patients	22-09-14	MT
Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients	22-09-14	CI
Larimar Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Larimar Therapeutics, Inc.

Equities

LRMR

US5171251003

Highlights

Filters